Identifying an early indicator of drug efficacy in patients (pts) with metastatic colorectal cancer (mCRC): A prospective evaluation of circulating tumor cells (CTC), 18F-fluorodeoxyglucose positron-emission tomography (PET), and the RECIST criteria (original) (raw)

Journal of Clinical Oncology, 2014

Abstract

3582 Background: The early determination of drug response is a keystone in oncology, and CTC is a promising biomarker in mCRC. This study investigated the prognostic significance of a novel dual-endpoint of ‘PET and CTC response’ at 4 weeks (wk), and of the conventional RECIST response at 10 wks post-1stline chemotherapy (chemo). Methods: All pts had a whole-body (WB) PET-CT (contrast) and CTC analysis (7.5ml blood) at baseline, a plain PET-CT and CTC analysis at 4 wks, and a WB-CT at 10 wks after starting chemo. CTCs were isolated using the cancer cell enrichment and detection kit (Milenyi Biotech). A positive CTC is defined as having: a positive red staining, round-to-oval morphology, size = or > 2 times that of lymphocyte. Evaluable lesions must have a SUVmax = or > 2 on PET and be measurable based on RECIST (version 1.0 and 1.1). PET response is defined as = or > 30% drop in the sum of SUVmax of target lesions, and CTC response is defined as ‘any level of drop’, or a ‘CTC < 3 cells’ at 4 wks. Results:...

Evaldo Soares hasn't uploaded this paper.

Let Evaldo know you want this paper to be uploaded.

Ask for this paper to be uploaded.